|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Entrada Therapeutics, Inc. (TRDA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
31,211,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Entrada Therapeutics is an intracellular therapeutics company. Endosomal Escape Vehicle (EEV) therapeutics are comprised of small cyclic peptides that are chemically conjugated to a range of specific and active biological therapeutics. Co.'s EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. Through its proprietary modular EEV platform, Co. is building a development portfolio of EEV therapeutic candidates designed to enable the intracellular delivery of therapeutics in various organs and tissues with an improved therapeutic index. Co. is focused on the development of EEV therapeutics for rare neuromuscular diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
45,368 |
45,368 |
45,368 |
86,315 |
Total Buy Value |
$641,941 |
$641,941 |
$641,941 |
$902,701 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
11 |
11 |
11 |
13 |
Total Shares Sold |
27,892 |
43,392 |
145,373 |
317,754 |
Total Sell Value |
$405,608 |
$646,444 |
$2,279,722 |
$5,092,515 |
Total People Sold |
4 |
4 |
5 |
5 |
Total Sell Transactions |
7 |
13 |
32 |
98 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-06-06 |
4 |
B |
$6.35 |
$245,377 |
I/I |
38,304 |
4,501,658 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-06-02 |
4 |
B |
$5.82 |
$15,383 |
I/I |
2,643 |
4,467,393 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-24 |
4 |
B |
$5.74 |
$137,100 |
I/I |
23,823 |
4,465,029 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-23 |
4 |
B |
$5.99 |
$46,923 |
I/I |
7,837 |
4,443,719 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-20 |
4 |
B |
$5.84 |
$98,424 |
I/I |
16,849 |
4,436,709 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-18 |
4 |
B |
$5.92 |
$206,534 |
I/I |
34,433 |
4,421,689 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-17 |
4 |
B |
$6.13 |
$113,474 |
I/I |
18,511 |
4,390,994 |
1.5 |
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2022-05-16 |
4 |
B |
$5.83 |
$110,692 |
I/I |
19,000 |
4,374,493 |
1.5 |
- |
|
Dowden Nathan J |
Chief Operating Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,263 |
72,607 |
|
- |
|
Doshi Dipal |
President and CEO |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,250 |
214,710 |
|
- |
|
Kreher Nerissa |
Chief Medical Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,344 |
15,544 |
|
- |
|
Wentworth Kory James |
Chief Financial Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,006 |
20,541 |
|
- |
|
Sethuraman Natarajan |
Chief Scientific Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,588 |
156,350 |
|
- |
|
Doshi Dipal |
President and CEO |
|
2022-01-13 |
4 |
OE |
$1.74 |
$17,400 |
D/D |
10,000 |
184,460 |
|
- |
|
Crowley John F |
Director |
|
2022-01-12 |
4 |
B |
$9.72 |
$48,575 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
Kreher Nerissa |
Chief Medical Officer |
|
2021-12-29 |
4 |
OE |
$2.10 |
$10,920 |
D/D |
5,200 |
5,200 |
|
- |
|
Baker Julian |
10% Owner |
|
2021-12-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,704,419 |
|
- |
|
Parmar Kush |
Director |
|
2021-11-02 |
4 |
B |
$20.00 |
$5,000,000 |
I/I |
250,000 |
1,132,357 |
2.25 |
- |
|
Parmar Kush |
Director |
|
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,827,224 |
882,357 |
|
- |
|
Foley Todd |
Director |
|
2021-11-02 |
4 |
B |
$20.00 |
$2,000,000 |
I/I |
100,000 |
4,425,784 |
2.25 |
- |
|
Foley Todd |
Director |
|
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
4,325,784 |
4,325,784 |
|
- |
|
Roche Finance Ltd |
10% Owner |
|
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,813,525 |
2,813,525 |
|
- |
|
Redmile Biopharma Investments Iii, L.p. |
10% Owner |
|
2021-11-02 |
4 |
B |
$20.00 |
$20,000,000 |
I/I |
1,000,000 |
1,954,420 |
1.5 |
- |
|
Redmile Biopharma Investments Iii, L.p. |
10% Owner |
|
2021-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
954,420 |
954,420 |
|
- |
|
Schwab Andrew J. |
10% Owner |
|
2021-11-02 |
4 |
B |
$20.00 |
$5,000,000 |
I/I |
250,000 |
1,132,357 |
1.5 |
- |
|
213 Records found
|
|
Page 8 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|